Psoriatic Arthritis

These data from the DISCOVER-2 study highlight improvements in patient-reported outcomes for patients who are biologic-naïve and have PsA.

This analysis indicates that a combined, 22-week Mediterranean and ketogenic diet for patients with psoriatic disease led to beneficial results.

These data highlight the potential window of opportunity for PsA patients’ diagnoses and any patient characteristics of those with longer diagnostic delays.

The findings in this research letter allow for greater understanding of residual joint pain modulators, with the overall goal being to improve health outcomes for those with PsA.

These data on patients with psoriatic arthritis point to risk levels for new adalimumab users as well as users of ustekinumab and etanercept.

A new study found the achievement of remission or low disease activity for PsA patients on apremilast was 53.8% by month 12.

On March 11, 2024, Acelyrin Inc. announced new positive data from clinical trial programs examining their IL-17A inhibitor izokibep in patients psoriatic arthritis and hidradenitis suppurativa.

Both biologic-naïve and biologic-experience patients receiving guselkumab demonstrated significantly higher ACR20 when compared with ustekinumab.

The submission could grant guselkumab its third indication, after being approved by the FDA for psoriasis and psoriatic arthritis.

A real-world cohort of patients with treatment-resistant active psoriatic arthritis receiving 6 months of guselkumab treatment achieved clinically meaningful improvements in pain and physical function.

At week 24, patients with moderate to severe PsA receiving risankizumab had a significantly higher ACR20 response rate when compared with placebo.

In an analysis of the DISCOVER-2 trial, guselkumab treatment reduced impairment in work productivity and improved general health status in PsA over 2 years.

Headache prevalence was significantly higher in the PsA and axSpA cohorts compared with healthy controls.

This announcement by UCB follows the results of four phase 3 studies on the use of bimekizumab for PsA, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

Patients with both psoriasis and psoriatic arthritis may be more likely to be tired based on symptom severity.

Most patients (82.6%) had minimal psoriasis skin involvement with a body surface area of < 3. However, 15.1% and 2.4% had a body surface area involvement of 3 – 10% and > 10, respectively.

Continuous improvement across all MDA domains was demonstrated over the 100-week timeframe, with approximately 70% of patients achieving near remission in swollen joint count, enthesitis, and the Psoriasis Area and Severity Index (PASI).

At the 6-month mark, between 73.2% to 78.6% of Canadian patients with psoriatic arthritis reported pain.

b/tsDMARD treatment led to a mean relative improvement of 41% for total work productivity in patients with psoriatic arthritis.

Results revealed a consistent safety profile with low rates of discontinuation and no increase in adverse events with prolonged treatment exposure in patients treated with ixekizumab.

The findings of this post-hoc analysis suggest a need for follow-up studies assessing and comparing JAK inhibition impact on the development of enthesitis.

Among other manifestations, patients with PsA and neuropathic pain tended to have higher leptin levels, poor sleep quality, and greater levels of fatigue.

This retrospective cohort study suggests the potential benefits of greater use of screening, though additional research on these predictive factors may be necessary as well.

The ACR's Psoriatic Arthritis Guidelines provides comprehensive recommendations for managing active psoriatic arthritis and aims to assist clinicians and patients in making informed decisions tailored to individual situations. Test your knowledge with this quiz.

These data on the success of twice-daily, 5 and 10 mg doses of tofacitinib may help inform clinicians in their practice as well as the health community in general.

These findings on both remission and low disease activity suggest that some individuals in routine clinical practice may see benefits after extending treatment with etanercept past 12 weeks.

Patients with rheumatic disease treated with biosimilar SDZ ETN reported high treatment persistence at month 12 as well as comparable safety and efficacy.

Patients with inflammatory arthritis demonstrated significantly increased odds of depression and anxiety health care encounters and use of anxiolytics and antidepressants.

Angus Worthing, MD, discusses the recent developments in rheumatology and his predictions for the future of treatment moving into 2024 and beyond.

In a new study, 31.9% of individuals with osteoporosis had depressive symptoms and 10% had probable depression.